Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C2 | P52895 | 4/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 4/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.44 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.44 |
| ▸ | ALB | P02768 | 1/20 | 0.44 |
| ▸ | SELL | P14151 | 1/20 | 0.43 |
| ▸ | SELP | P16109 | 1/20 | 0.43 |
| ▸ | ERN1 | O75460 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ASPH | Q12797 | 1/20 | 0.41 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20505208 | 0.83 | ALB (0.48) | AKR1C2AKR1C1AKR1C3AKR1C4ALB | |
| SCHEMBL3540940 | 0.83 | CYP1A2 (0.44) | AKR1C2AKR1C1AKR1C3AKR1C4ALB | |
| SCHEMBL4851530 | 0.81 | KDM4E (0.42) | AKR1C2AKR1C1AKR1C3AKR1C4ALB | |
| SCHEMBL1982182 | 0.80 | SELL (0.60) | AKR1C2AKR1C1AKR1C3AKR1C4ALB | |
| SCHEMBL16122325 | 0.79 | KDM4E (0.50) | AKR1C2AKR1C1AKR1C3AKR1C4ALB | |
| SCHEMBL23501039 | 0.78 | SELL (0.64) | AKR1C2AKR1C1ALBSELLSELP | |
| SCHEMBL6508228 | 0.78 | AKR1C3 (0.47) | AKR1C2AKR1C1AKR1C3AKR1C4SELL | |
| SCHEMBL31455903 | 0.78 | ALB (0.57) | AKR1C2AKR1C1ALBSELLSELP | |
| SCHEMBL7880433 | 0.78 | ALB (0.57) | AKR1C2AKR1C1ALBSELLSELP | |
| SCHEMBL206341 | 0.78 | EPRS1 (0.40) | ALBKDM4EASPHKDM8CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180318311-A1 | TRICYCLIC 2-QUINOLINONES AS ANTIBACTERIALS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-11-08 | — | — | US | disclosed |
| EP-1664062-B1 | ISOTHIAZOLOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS | ACHILLION PHARMACEUTICALS INC (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20120114601-A1 | NEW ISOTHIAZOLOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120114601-A1 | NEW ISOTHIAZOLOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-8114888-B2 | Isothiazoloquinolones and related compounds as anti-infective agents | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114888-B2 | Isothiazoloquinolones and related compounds as anti-infective agents | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20110223132-A1 | ISOTHIAZOLOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS | ACHILLION PHARMACEUTICALS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110223132-A1 | ISOTHIAZOLOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS | ACHILLION PHARMACEUTICALS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| EP-1848723-B1 | NEW ISOTHIAZOLOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS | ACHILLION PHARMACEUTICALS INC (US) | 2010-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180318311-A1 | TRICYCLIC 2-QUINOLINONES AS ANTIBACTERIALS | TOP1, TOP2A, TOP2B | AKR1C2 1562/4885AKR1C1 1528/4885AKR1C3 1409/4885 |
| US-20120114601-A1 | NEW ISOTHIAZOLOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS | TOP1, RECQL, IRF3 | AKR1C2 1306/4885AKR1C1 856/4885AKR1C3 1015/4885 |
| US-20110223132-A1 | ISOTHIAZOLOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS | TOP1, IRF3, RECQL | AKR1C2 1087/4885AKR1C1 677/4885AKR1C3 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.